A recent settlement has the potential to extend the exclusivity of Gilead’s Biktarvy, the leading HIV medication, until 2036. This development is significant for the pharmaceutical landscape, as it prolongs Gilead’s market dominance and delays the entry of generic competitors. The implications of this exclusivity are profound, particularly for stakeholders in regulatory, QA/QC, and sourcing sectors, who must navigate the evolving market dynamics and potential shifts in pricing strategies.
In parallel, the CDC has updated its vaccine schedule, reflecting ongoing adjustments to public health strategies in response to emerging infectious diseases. This update is crucial for pharmaceutical companies involved in vaccine production and distribution, as it may affect supply chain logistics and regulatory compliance. As the industry adapts to these changes, professionals must remain vigilant in understanding the regulatory landscape and its impact on product development and market access.
Get started today with Solo access →
